J&J Sees International OTC Presence, Pfizer Pickups As Growth Engines
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson's over-the-counter version of the antihistamine Zyrtec will not have a period of marketing exclusivity following its planned year-end launch and likely will face competitors immediately, the firm said during a June 7 meeting with financial analysts in New Brunswick, N.J
You may also be interested in...
Johnson & Johnson Starts Downsizing Plan, PCH Integration Stays On Track
Johnson & Johnson executives are touting the strength of the firm's consumer products businesses as they implement a plan to generate up to $1.6 billion in savings through consolidations and layoffs in J&J's pharmaceutical and medical device operations
Johnson & Johnson Starts Downsizing Plan, PCH Integration Stays On Track
Johnson & Johnson executives are touting the strength of the firm's consumer products businesses as they implement a plan to generate up to $1.6 billion in savings through consolidations and layoffs in J&J's pharmaceutical and medical device operations
Johnson & Johnson Starts Downsizing Plan, PCH Integration Stays On Track
Johnson & Johnson executives are touting the strength of the firm's consumer products businesses as they implement a plan to generate up to $1.6 billion in savings through consolidations and layoffs in J&J's pharmaceutical and medical device operations